On November 2, 2023 Omeros Corporation (Nasdaq: OMER) reported that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), to be held December 9-12, 2023 in San Diego (Press release, Omeros, NOV 2, 2023, View Source [SID1234636840]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Both abstracts were published today and are now available on the ASH (Free ASH Whitepaper) website at www.hematology.org. Details of the congress presentations are found below.
OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients (Abstract #573)
Session Name: 508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy from Clinical Trials
Date: Sunday, December 10, 2023
Podium Presentation Time: 5:00 p.m. PT
Location: San Diego Convention Center, Room 7
Alternative Pathway MASP-3 Inhibitor OMS906 Effectively and Potently Inhibits Complement-Mediated Hemolysis in Preclinical Models Mechanistically Similar to Paroxysmal Nocturnal Hemoglobinuria (Abstract #4082)
Session Name: 508. Bone Marrow Failure: Acquired: Poster III
Date: Monday, December 11, 2023
Presentation Time: 6:00 p.m. – 8:00 p.m. PT
Location: San Diego Convention Center, Halls G-H
The presentation materials associated with each abstract will be made available on Omeros’ website at www.omeros.com following the congress presentations.
About OMS906
OMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The complement system plays a central role in inflammation and becomes activated as a result of tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complement factor D, MASP-3 is believed to be the premier target in the alternative pathway – it has the lowest native circulating level and low relative clearance compared to the other alternative pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition leaves intact the lytic arm of the classical pathway, important for fighting infection. Also, unlike other components of the alternative pathway, MASP-3 is believed not to be an acute phase reactant, which could provide a significant advantage to MASP-3 inhibitors, like OMS906, over other alternative pathway inhibitors. MASP-3 inhibitors are thought to have preventive or therapeutic effects across a broad range of diseases including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS), atypical HUS, traumatic brain injury, arthritis, wet age-related macular degeneration, ischemia-reperfusion injury, transplant-related complications and other immune-related disorders.